Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erythritol, sucrose, and sucralose elicit similar reward responses after flavor preference learning in healthy humans.

Physiology & behavior·2026
Same author

Early transmural response assessed by intestinal ultrasound predicts long-term clinical remission in patients with IBD: Results from the TRUST BEYOND study.

Inflammatory bowel diseases·2026
Same author

Predictors of Fasting Endogenous Erythritol and Erythronate Concentrations in Humans: Cross-Sectional and Post-Bariatric Surgery Analyses.

International journal of molecular sciences·2025
Same author

Effects of Oral Xylitol, Sucrose, and Acesulfame Potassium on Total Energy Intake During a Subsequent <i>ad libitum</i> Test Meal: A Randomized, Controlled, Crossover Trial in Healthy Humans.

Nutrients·2025
Same author

Efficacy and Safety of Anthocyanin-Rich Extract in Patients with Ulcerative Colitis: A Randomized Controlled Trial.

Nutrients·2024
Same author

Fecal urgency and incontinence in inflammatory bowel disease perceived by physician and patient: Results from the Swiss fecal urgency survey.

United European gastroenterology journal·2024
Same journal

Metamizole-induced agranulocytosis: utilisation trends, pharmacovigilance signals and regulatory risk-minimisation in Switzerland.

Swiss medical weekly·2026
Same journal

Female genital mutilation/cutting and risk of obstetric anal sphincter injury at delivery.

Swiss medical weekly·2026
Same journal

Drug prescription before and after implementation of a CPOE system on the Paediatric Intensive Care Unit: a quality improvement study.

Swiss medical weekly·2026
Same journal

Trends in health- and lifestyle-related aspects in women of childbearing age: analysis of Swiss Health Survey data between 1992 and 2022.

Swiss medical weekly·2026
Same journal

Microplastics in the air and potential health risks - a narrative review.

Swiss medical weekly·2026
Same journal

Potentially inappropriate medication: prevalence, risk of hospitalisation and associated healthcare costs in the general older population of Switzerland.

Swiss medical weekly·2026
See all related articles

Related Experiment Video

Updated: May 31, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

Treatment algorithm for moderate to severe ulcerative colitis.

Michael Manz1, Pierre Michetti, Frank Seibold

  • 1Department of Gastroenterology and Internal Medicine, St. Claraspital Basel, Switzerland. michael.manz@claraspital.ch

Swiss Medical Weekly
|June 28, 2011
PubMed
Summary
This summary is machine-generated.

Managing ulcerative colitis (UC) is challenging. This review details treatment strategies for moderate to severe UC, incorporating new therapies like infliximab and ciclosporin.

More Related Videos

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

Related Experiment Videos

Last Updated: May 31, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

Area of Science:

  • Gastroenterology and Clinical Medicine
  • Immunology and Inflammation

Background:

  • Ulcerative colitis (UC) management remains complex despite reduced mortality.
  • Traditional corticosteroid therapy has been augmented by biologics and immunosuppressants.
  • Focus is on moderate to severe UC cases.

Purpose of the Study:

  • To review and update treatment strategies for moderate to severe ulcerative colitis.
  • To provide evidence-based recommendations for clinical practice.
  • To develop treatment algorithms for daily use.

Main Methods:

  • Literature review of current publications, guidelines, and reviews.
  • Consensus discussion among Swiss experts in gastroenterology.
  • Development of clinical scenarios and treatment algorithms.

Main Results:

  • Identification of four distinct clinical scenarios in UC management.
  • Integration of corticosteroids, ciclosporin, and infliximab into treatment plans.
  • Creation of comprehensive algorithms for practical application.

Conclusions:

  • Updated treatment recommendations for moderate to severe UC.
  • Algorithms facilitate evidence-based decision-making in daily practice.
  • Multidisciplinary expert consensus guides therapeutic approaches.